Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DanNORMS: Rituximab vs Ocrelizumab in Active Multiple Sclerosis
NCT04688788Phase 3Active, not recruiting
- Sponsor
- Rigshospitalet
- Start
- Apr 2021
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in multiple sclerosis (MS), sponsored by Rigshospitalet. Started Apr 2021; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04688788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688788.